Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - aciclovir 200mg; aciclovir 200mg - dispersible tablet - 200 mg - active: aciclovir 200mg excipient: aluminium magnesium silicate hypromellose indigo carmine macrogol 400 macrogol 8000 magnesium stearate microcrystalline cellulose povidone sodium starch glycolate active: aciclovir 200mg excipient: aluminium magnesium silicate hypromellose macrogol 400 macrogol 8000 magnesium stearate microcrystalline cellulose povidone sodium starch glycolate titanium dioxide - zovirax dispersible tablets are indicated for the treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes. zovirax dispersible tablets are indicated for the suppression (prevention of recurrences) of recurrent herpes simplex infections in immune-competent patients. zovirax dispersible tablets are indicated for the prophylaxis of herpes simplex infections in immune-compromised patients.

Singapur - anglès - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - aciclovir - tablet - 200 mg - aciclovir 200 mg

Israel - anglès - Ministry of Health

glaxo smith kline (israel) ltd - aciclovir - tablets - aciclovir 200 mg - aciclovir - aciclovir - •zovirax tablets are indicated for the treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes (excluding neonatal hsv and severe hsv infections in immunocompromised children).•zovirax tablets are indicated for the suppression (prevention of recurrences) of recurrent herpes simplex infections in immunocompetent patients.•zovirax tablets are indicated for the prophylaxis of herpes simplex infections in immunocompromised patients.•zovirax tablets are indicated for the treatment of varicella (chickenpox) and herpes zoster (shingles) infections

Israel - anglès - Ministry of Health

glaxo smith kline (israel) ltd - aciclovir - tablets - aciclovir 400 mg - aciclovir - aciclovir - •zovirax tablets are indicated for the treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes (excluding neonatal hsv and severe hsv infections in immunocompromised children).•zovirax tablets are indicated for the suppression (prevention of recurrences) of recurrent herpes simplex infections in immunocompetent patients.•zovirax tablets are indicated for the prophylaxis of herpes simplex infections in immunocompromised patients.•zovirax tablets are indicated for the treatment of varicella (chickenpox) and herpes zoster (shingles) infections

Israel - anglès - Ministry of Health

glaxo smith kline (israel) ltd - aciclovir - tablets dispersible - aciclovir 800 mg - aciclovir - aciclovir - zovirax tablets 800 mg are indicated for the treatment of varicella (chickenpox) and herpes zoster (shingles) infections (excluding neonatal hsv and severe hsv infections in immunocompromised children).zovirax 800mg tablets is recommended in children over the age of 6.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - aciclovir, quantity: 200 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; copovidone; magnesium stearate - adults; treatment of first episode (primary or nonprimary) genital herpes and the management of recurrent episodes of genital herpes in certain patients. treatment of acute attacks of herpes zoster (shingles) when the duration of rash is less than 72 hours. the management of patients with advanced symptomatic hiv disease (cd4+ counts <150 x 10 6/l). genital herpes initial episodes. the duration of viral shedding is reduced very significantly; the duration of pain and time to healing are also reduced. the promptness of initiation of therapy and/or the patient's prior exposure to herpes simplex virus may influence the degree of benefit from therapy. intravenous aciclovir should be considered in patients in whom prostration, cns involvement or inability to take oral medication requires hospitalisation and initiation or more aggressive management. aciclovir does not prevent the establishment of latency in initial episodes.,recurrent episodes. suppression. in patients with frequent recurrences, suppressive therapy

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - aciclovir - dispersible tablet - 200mg

Kenya - anglès - Pharmacy and Poisons Board

glaxosmithkline pharmaceutical kenya limited likoni road industrial area nairobi - acyclovir - tablet - 200mg - antivirals for systemic use:

Emirats Àrabs Units - anglès - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

al baker trading establishment spain - 25's( 5 x 5's blister) - tablet - 200mg / tablet - eye-anti-infective eye preparations, skin-anti-infective skin preparations, infections-antiviral

Canadà - anglès - Health Canada

glaxosmithkline inc - acyclovir - tablet - 200mg - acyclovir 200mg - nucleosides and nucleotides